Lilly Gains New Indication For Forteo, But Also A REMS And Patient Registry

Lilly is setting up a voluntary Forteo patient registry to collect data on potential bone cancer risk as part of FDA's approval of a new indication for the osteoporosis treatment. The company is also instituting a Risk Evaluation and Mitigation Strategy to control for the risk